Abstract:Background Protection of cancer cells by the stromal microenvironment is an important drug-resistant mechanism in vivo, and poses a major challenge in cancer treatment. Based on our recent findings that auranofin (AF), an anti-rheumatic drug known to inhibit thioredoxin reductases (TrxR), was effective against several cancer models in vivo, this study tested the ability of AF to eliminate cancer cells in the tumor stromal microenvironment and investigated the underlying mechanisms. Methods Cytotoxic effect of AF on 33 cancer cell lines in vitro was determined by MTS assay to identify AF- sensitive cancer cells. Further cytotoxic effect of AF on the identified cancer cells was determined by flow cytometry analysis in stromal co-culture system. Mitochondrial bioenergetics assays using the Seahorse XF24 analyzer, mass spectrometry analyses, and enzyme activity assays were used in the mechanistic study. For in vivo study, lymphoma xenograft models were utilized to evaluate the in vivo therapeutic activity of AF in mice. Results We unexpectedly found that AF exhibited higher therapeutic activity against lymphoma cells in stromal microenvironment compared to lymphoma cell treated with AF without stromal cells. Mechanistic study showed that AF impacted energy metabolism by inhibiting the glycolytic enzyme GAPDH and suppressing mitochondrial electron transport complex II, leading to ATP depletion. Surprisingly, inhibition of TrxR seemed not critical for its anticancer activity, as genetic silencing of TrxR1 and TrxR2 did not significantly affect cell viability. Co-culture of lymphoma cells with stromal cells enhanced the expression of TrxR1, which became an ROS-generating molecule when interacting with AF. The AF-induced ATP depletion plus ROS generation together effectively killed the cancer cells in stromal microenvironment, and significantly suppressed tumor growth in mice bearing mantle cell lymphoma xenografts. Conclusions Our study reveals a novel mechanism by which AF eliminates cancer cells in tumor microenvironment by impacting cancer metabolism and promoting ROS generation, and suggests a possibility to repurpose this anti-rheumatic drug for treatment of lymphoma and overcome drug resistance in stromal microenvironment.

Enhancement of auranofin-induced lung cancer cell apoptosis by selenocystine, a natural inhibitor of TrxR1 in vitro and in vivo

Enhancement of Auranofin-Induced Apoptosis in MCF-7 Human Breast Cells by Selenocystine, a Synergistic Inhibitor of Thioredoxin Reductase

Synergy Between Auranofin And Celecoxib Against Colon Cancer In Vitro And In Vivo Through A Novel Redox-Mediated Mechanism

Selenocystine Potentiates Cancer Cell Apoptosis Induced by 5-Fluorouracil by Triggering Reactive Oxygen Species-Mediated DNA Damage and Inactivation of the ERK Pathway

Strategy to Enhance the Therapeutic Effect of Doxorubicin in Human Hepatocellular Carcinoma by Selenocystine, A Synergistic Agent That Regulates the Ros-Mediated Signaling

Auranofin Inhibition of Thioredoxin Reductase Sensitizes Lung Neuroendocrine Tumor Cells (NETs) and Small Cell Lung Cancer (SCLC) Cells to Sorafenib as well as Inhibiting SCLC Xenograft Growth

Effective Elimination of Lymphoma Cells in Stromal Microenvironment by Double Impact on ROS and ATP Metabolism Using Auranofin

Inducing Ubiquitination and Degradation of TrxR1 Protein by LW-216 Promotes Apoptosis in Non-Small Cell Lung Cancer Via Triggering ROS Production

Elimination of Stem-Like Cancer Cell Side-Population by Auranofin Through Modulation of ROS and Glycolysis.

Synergism Between Thioredoxin Reductase Inhibitor Ethaselen and Sodium Selenite in Inhibiting Proliferation and Inducing Death of Human Non-Small Cell Lung Cancer Cells.

Inhibition of thioredoxin reductase by auranofin induces apoptosis in adriamycin-resistant human K562 chronic myeloid leukemia cells.

Augmented antitumor effects of combination therapy of cisplatin with ethaselen as a novel thioredoxin reductase inhibitor on human A549 cell in vivo

Synergistic effect of ethaselen and selenite treatment against A549 human non-small cell lung cancer cells.

Selenium Sensitizes MCF-7 Breast Cancer Cells to Doxorubicin-Induced Apoptosis Through Modulation of Phospho-Akt and Its Downstream Substrates

Cancer Therapy by Targeting Thioredoxin Reductase Based on Selenium-Containing Dynamic Covalent Bond

Selenium Atom-Polarization Effect Determines TrxR-Specific Recognition of Metallodrugs.

Synergistic Lethality Between Auranofin-Induced Oxidative DNA Damage and ATR Inhibition in Cancer Cells

Selenadiazole Derivatives As Potent Thioredoxin Reductase Inhibitors That Enhance the Radiosensitivity of Cancer Cells

Mitochondrion-targeted selenium nanoparticles stabilized by Sargassum fusiforme polysaccharides increase reactive oxygen species-mediated antitumour activity

Auranofin induces apoptosis by ROS-mediated ER stress and mitochondrial dysfunction and displayed synergistic lethality with piperlongumine in gastric cancer.